AI Equipped OS-SiA Digital Pathology Scanner Developed by OptraSCAN Granted US Patent
OptraSCAN®, the main end-to-end digital pathology resolution supplier, introduced its digital pathology scanner OS-SiA has been granted US patent – No 2020/0334814 A1 by the USA Patent and Trademark Workplace. OS-SiA has inbuilt intelligence to scan, index and analyze pathological samples concurrently. This can profit the end-user to view the entire slide scanned picture together with analyzed output as an overlay throughout their assessment course of.
OptraSCAN’s digital pathology scanner OS-SiA
The patent describes a method invented by OptraSCAN, the AI-enabled digital pathology scanner OS-SiA routinely identifies specimens to scan and concurrently analyses the tissue or cell space being scanned. OS-SiA is the trade’s first AI-enabled digital scanner that may present real-time predictive evaluation and actionable insights.
“At the moment, the digital pathology slide scanners are restricted to partial or complete slide picture acquisition and digitization into a picture. Our next-generation scanner OS-SiA scans and analyses concurrently eliminating the necessity for extra processing functions,” mentioned Abhi Gholap, Founder & CEO, OptraSCAN. “This patent highlights our fixed efforts to enhance the adoption of digital pathology options and assist the pathology group.”
OS-SiA could be embedded within the present collection of its cloud-enabled brightfield scanners specifically OS-Lite & OS-Extremely. The customized algorithms present real-time ROI detection whereas scanning, cell quantification for IHC/HNE markers, morphological measurements constructed utilizing the core library. The entire slide picture could be seen in an area/web-based/cloud-based picture viewer. The deep studying computational module is offered for self-learning within the scanning system.
“That is the sort of breakthrough we have to speed up the adoption of digital pathology, simultaneous scanning and evaluation will assist pathologists make quicker choices and enhance affected person outcomes,” Dr. Zu-Hua Gao MD, Medical Advisor at OptraSCAN and Chair – Pathology, College of British Columbia